CNTX Context Therapeutics Inc
Company Analysis
Latest News
🟢 CNTX makes sharp 10.3% jump
CNTX is trading at $0.67, up 10.3% versus the comparison close of $0.61 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 CNTX is trading 5.2% up today with no clear company-specific catalyst
CNTX is trading at 5.2% up now at $0.64 after a sharp 9.8% gain in the previous session. There are no fresh company-specific headlines, earnings, FDA updates,...
🟢 CNTX makes sharp 10.1% jump
CNTX is trading at $0.61, up 10.1% versus the comparison close of $0.55 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 CNTX is trading 6.3% up today as a technical bounce after recent downside
CNTX is trading 6.3% up today at $0.59, continuing a modest rebound after heavy longer-term downside pressure. • The gain appears to be a technical bounce...
🟢 CNTX is trading 5.1% up today as a modest bounce within a broader downtrend
CNTX is trading 5.1% up today at $0.61 as the stock stages a modest bounce following recent sharp volatility and heavy longer-term downside pressure. • There...
Context Therapeutics Stockholders Approve Increase in Authorized Common Stock to 300 Million
Context Therapeutics Inc. announced that its stockholders have approved an amendment to the company's Certificate of Incorporation to increase the number of...
🟢 CNTX is trading 5.3% up today on technical rebound and bargain hunting
CNTX is trading 5.3% up at $0.59 on a technical rebound and bargain-hunting move following a sharp two-day slide earlier this week. • The current gains appear...
🟢 CNTX is trading 5.3% up today on a technical bounce after recent volatility
CNTX is trading 5.3% up at $0.61 as a technical bounce and bargain-hunting follow yesterday’s double-digit drop. • No fresh company-specific news or filings...
🔴 CNTX makes sharp 10.7% drop
CNTX is trading at $0.58, down 10.7% versus the comparison close of $0.65 during regular trading. This is a price-movement alert; no separate company-specific...
🔴 CNTX is trading 5.1% down today as the rebound from positive CTIM-76 data loses steam
CNTX is trading at $0.62 (5.1% down) as its multi-day rebound, fueled by positive CTIM-76 Phase 1 data and supportive analyst commentary, begins to fade. •...
🟢 CNTX is trading 9.5% up today, extending its rebound on positive CTIM-76 data and analyst support
CNTX is trading 9.5% up at $0.69 as it extends its rebound following last week’s CTIM-76 Phase 1 data and bullish analyst commentary. • Shares are recovering...
🟢 Context Therapeutics Inc gains after positive CTIM-76 Phase 1 trial results and analyst endorsements
• Context Therapeutics Inc is trading at $0.67 (+6.03%) today, rebounding after the company reported positive interim Phase 1 clinical data for its CTIM-76...
🟢 Context Therapeutics Inc is trading 5.2% up today on bargain-hunting after a sharp selloff
Context Therapeutics Inc is trading 5.2% up at $0.63 as shares see a modest rebound following several days of heavy losses linked to clinical trial results. •...
Context Therapeutics Called Its Cancer Data "Positive" — So Why Have Investors Wiped Out 59% of Its Stock in Three Days?
Shares of Context Therapeutics cratered this week after the company released interim Phase 1 results for its lead ovarian cancer drug, raising a brutal...
🔴 Context Therapeutics Inc is trading 8% down today on follow-through selling after CTIM-76 data release
Context Therapeutics Inc is trading at $0.60 (8% down) as the stock extends its sharp decline following the release of interim Phase 1 data for its ovarian...
🔴 Context Therapeutics Inc is trading 5.3% down today, extending a sell-off after Phase 1 data for ovarian cancer candidate CTIM-76
Context Therapeutics Inc is trading at $0.64 (5.3% down), extending a sharp sell-off triggered by interim Phase 1 data for its ovarian cancer candidate,...
🔴 Context Therapeutics Inc is trading 6.4% down today as profit-taking continues after CTIM-76 data
Context Therapeutics Inc is trading at $0.64 (6.4% down) in pre-market, extending a sharp sell-off following the release of interim Phase 1 data for its...
Context Therapeutics Reports Positive Phase 1 Data for CTIM-76 in Ovarian Cancer
Context Therapeutics Inc. announced positive interim efficacy and safety results from its ongoing Phase 1 clinical trial of CTIM-76, its investigational...
🔴 Context Therapeutics Inc is trading 34.68% down today after a sharp intraday selloff
Context Therapeutics Inc is trading at $0.91 (-34.68%) following a sharp intraday selloff, though no specific company catalyst has been confirmed to drive the...
🟢 Context Therapeutics Inc makes sharp 12.2% jump
CNTX is trading at $1.56, up 12.2% versus the comparison close of $1.39 during pre-market. This is a price-movement alert; no separate company-specific...